세계 바이오베터 시장 - 업계 분석, 규모, 점유율, 성장 및 동향 예측(2031년)

Biobetters Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

US $ 4,995 ￦ 6,919,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,768,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,684,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 바이오베터 시장 규모는 2024년부터 2031년까지 강력한 성장을 보이고 있습니다. 이 성장 궤도는 앞으로도 계속되고 2024년부터 2031년에 걸친 CAGR은 10%로 예상되고 있습니다. 2024년 바이오베터 세계 시장 규모는 600억 달러에 이르렀고, 2031년에는 1,150억 달러에 이를 것으로 예상됩니다.

바이오 베터는 바이오수페리어라고도 불리며, 기존의 바이오 의약품과 동일한 카테고리에 속하는 재조합 단백질 의약품의 일종입니다. 바이오베터는 기존의 바이오 의약품과 같은 카테고리에 속하지만, 원약과 동일하지 않다는 점에서 다릅니다. 바이오베터는 임상 효과를 높이고, 내약성을 개선하고, 투여 횟수를 줄이고, 부작용을 줄이기 위해 고안되었습니다. 뛰어난 치료 효과, 부작용 감소, 비용 효율적인 제조 방법, 비특허 및 시장 독점성, 제품 반감기 연장, 투여 횟수 감소, 매력적인 투자 기회 등 바이오 베터는 많은 이점을 제공합니다. 따라서 바이오 베터 시장은 성장할 전망입니다.

바이오베터는 기존의 생물학적 제제를 개량한 것으로, 치료 효과의 향상, 부작용의 경감, 투여 횟수의 감소를 실현합니다. 이러한 탁월한 효능과 투여 횟수가 적은 환자의 컴플라이언스에 기여하고 시장의 상당한 성장을 이끌 것으로 예상됩니다.

바이오베터는 PEG화 및 알부민 치환과 같은 최신 기술을 도입한 생물학적 제제와 유사한 공정으로 제조됩니다. 이러한 기술은 바이오 베터의 제조를 간소화하고 생물학적 제형에 비해 비용 효율성이 높습니다. 생물 제제의 개발 기간이 약 15년으로 긴 반면, 바이오베터의 개발 기간은 약 10년으로 짧습니다. 바이오 시밀러의 개발 비용은 바이오 베터의 약 절반이지만 치료 효과는 바이오 베터가 더 좋습니다.

바이오 의약품 제조업체와 투자자의 개량형 제제 개발을 위한 지속적인 연구 활동은 바이오베터 시장의 확대를 추진하고 있습니다. 선진적인 생물물리학적·생화학적 접근이 등장하여 업계의 성장에 큰 기세를 가져오고 있습니다.

본 보고서에서는 세계 바이오베터 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별, 적응증별, 투여경로별, 유통채널별, 지역별 동향 및 시장 진출기업의 경쟁 동향 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아의 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 바이오베터스 시장 전망(2018-2031년)

• 세계 바이오베터 시장 전망, 제품 유형별 금액(10억 달러)(2018-2031년)
• 세계 바이오베터 시장 전망, 적응증별 금액(10억 달러)(2018-2031년)
• 세계 바이오베터 시장 전망, 투여 경로별 금액(10억 달러)(2018-2031년)
• 세계 바이오베터 시장 전망, 유통 채널별 금액(10억 달러)(2018-2031년)
• 세계 바이오베터 시장 전망, 지역별 금액(10억 달러)(2018-2031년)

제4장 북미의 바이오베터스 시장 전망(2018-2031년)

제5장 유럽의 바이오베터스 시장 전망(2018-2031년)

제6장 아시아태평양의 바이오베터스 시장 전망(2018-2031년)

제7장 라틴아메리카의 바이오베터스 시장 전망(2018-2031년)

제8장 중동 및 아프리카의 바이오베터스 시장 전망(2018-2031년)

제9장 경쟁 구도

• 제품과 적응증의 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁 대시보드
• 기업 프로파일
  • F.Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Sanofi SA
  • SERVIER
  • Porton Biopharma Limited
  • Eli Lily and Company
  • Novo Nordisk A/S
  • Biogen Inc.
  • CSL Behring GmbH
  • Teva Pharmaceutical Industries Ltd.

제10장 부록

JHS

영문 목차

영문목차

The global Biobetters Market has demonstrated robust growth from 2024 to 2031. This growth trajectory is set to continue, with an anticipated steady CAGR of 10% expected between 2024 and 2031. In 2024, the global Biobetters Market reached a size of US$ 60 billion, and it is projected to attain a valuation of US$ 115 billion by 2031.

Overview of the Biobetters Market

Biobetters, also known as biosuperiors, represent a class of recombinant protein drugs that belong to the same category as existing biopharmaceuticals. However, they are distinct in that they are not identical to the source drugs. Biobetters are designed to enhance clinical efficacy, improve tolerance, reduce dosing frequency, and lower side effects. The Biobetters Market is poised to grow due to their numerous advantages, including superior therapeutic efficacy, reduced side effects, cost-effective production methods, non-patent and market exclusivity, extended product half-life, reduced dosage frequency, and attractive investment opportunities.

Factors Driving the Growth of the Biobetters Market

"High Efficacy and Few Side Effects"

Biobetters are engineered to be improved versions of existing biologics, offering enhanced therapeutic benefits, reduced side effects, and less frequent dosing. This superior efficacy and lower dosing frequency contribute to patient compliance and are expected to drive significant market growth.

"Simple and Cost-effective Manufacturing Process"

Biobetters are manufactured using processes similar to biologics, with the incorporation of modern technologies such as pegylation and albumin replacement. These techniques have streamlined the production of biobetters, making it more cost-effective compared to biologics. Biobetters have a shorter development timeline, approximately 10 years, in contrast to the longer development period of around 15 years for biologics. While biosimilars require roughly half the development cost of biobetters, the latter offer superior therapeutic effectiveness.

"Increasing Research Activities"

Continuous research efforts by biopharmaceutical manufacturers and investors to develop improved formulations are driving the expansion of the biobetters market. Advanced biophysical and biochemical approaches have emerged, providing significant momentum to the industry's growth.

"Increased Investment in Developing Therapeutic Agents"

The growing investment in developing therapeutic agents with enhanced effectiveness and safety profiles for conditions such as cancers and autoimmune diseases is influencing the biobetters market positively. Efforts to mitigate the economic impact of chronic diseases have led to substantial investments in new drug development, further fueling market growth.

Challenges Faced by the Biobetters Market

"High Investments Required for R&D Activities"

The development of novel medicinal drugs, including biobetters, demands substantial investments in research and development, which can act as a limitation on market growth. However, the post-COVID-19 era has witnessed a significant surge in R&D spending for the development of biobetters. Additionally, increasing biosimilar competition poses challenges to market expansion.

Impact of COVID-19 on the Biobetters Market

"Increase in Investment for Developing Novel Biobetters"

The COVID-19 pandemic has prompted a notable increase in R&D investment for the development of novel biobetters. Manufacturers and investors in the biobetter industry are actively working on improving formulations, resulting in numerous novel medications in the pipeline or undergoing clinical trials.

Competitive Landscape

The Biobetters market is characterized by intense competition, with several major players dominating the industry. Market participants are focusing on mergers and strategic alliances to expand their product portfolios and enhance market share, leveraging the industry's growth phase.

Key Companies Profiled

• F.Hoffmann-La Roche AG
• Merck & Co. Inc.
• Sanofi SA
• SERVIER
• Porton Biopharma Limited
• Eli Lilly and Company
• Novo Nordisk A/S
• Biogen Inc.
• CSL Behring GmbH
• Teva Pharmaceutical Industries Ltd.

Biobetters Market Segmentation

Biobetters Market by By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Biobetters Market By Molecule Type

• G-CSF Biobetters
• Insulin Biobetters
• Erythropoietin Biobetters
• Monoclonal Antibodies Biobetters
• Others

Biobetters Market by Disease Indication

• Cancer
• Diabetes
• Genetic disease
• Neurological Disorders
• Others

Biobetters Market by Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Biobetters Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Biobetters Market Outlook, 2018 - 2031

• 3.1. Global Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Erythropoietin Biobetters
    • 3.1.1.2. G-CSF Biobetters
    • 3.1.1.3. Interferon Biobetters
    • 3.1.1.4. Insulin Biobetters
    • 3.1.1.5. Monoclonal Antibodies Biobetters
    • 3.1.1.6. Anti-haemophilic Factor
    • 3.1.1.7. Others
• 3.2. Global Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Diabetes
    • 3.2.1.2. Cancer
    • 3.2.1.3. Renal Disease
    • 3.2.1.4. Neurodegenerative Disease
    • 3.2.1.5. Genetic Disorders (Haemophilia)
    • 3.2.1.6. Others
• 3.3. Global Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Subcutaneous
    • 3.3.1.2. Intravenous
• 3.4. Global Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. Hospital Pharmacies
    • 3.4.1.2. Retail Pharmacies
    • 3.4.1.3. Online Pharmacies
• 3.5. Global Biobetters Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.5.1. Key Highlights
    • 3.5.1.1. North America
    • 3.5.1.2. Europe
    • 3.5.1.3. Asia Pacific
    • 3.5.1.4. Latin America
    • 3.5.1.5. Middle East & Africa

4. North America Biobetters Market Outlook, 2018 - 2031

• 4.1. North America Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Erythropoietin Biobetters
    • 4.1.1.2. G-CSF Biobetters
    • 4.1.1.3. Interferon Biobetters
    • 4.1.1.4. Insulin Biobetters
    • 4.1.1.5. Monoclonal Antibodies Biobetters
    • 4.1.1.6. Anti-haemophilic Factor
    • 4.1.1.7. Others
• 4.2. North America Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Diabetes
    • 4.2.1.2. Cancer
    • 4.2.1.3. Renal Disease
    • 4.2.1.4. Neurodegenerative Disease
    • 4.2.1.5. Genetic Disorders (Haemophilia)
    • 4.2.1.6. Others
• 4.3. North America Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Subcutaneous
    • 4.3.1.2. Intravenous
• 4.4. North America Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.4.1. Key Highlights
    • 4.4.1.1. Hospital Pharmacies
    • 4.4.1.2. Retail Pharmacies
    • 4.4.1.3. Online Pharmacies
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis
• 4.5. North America Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.5.1. Key Highlights
    • 4.5.1.1. U.S. Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 4.5.1.2. U.S. Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.5.1.3. U.S. Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.5.1.4. U.S. Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.5.1.5. Canada Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 4.5.1.6. Canada Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.5.1.7. Canada Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.5.1.8. Canada Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Biobetters Market Outlook, 2018 - 2031

• 5.1. Europe Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Erythropoietin Biobetters
    • 5.1.1.2. G-CSF Biobetters
    • 5.1.1.3. Interferon Biobetters
    • 5.1.1.4. Insulin Biobetters
    • 5.1.1.5. Monoclonal Antibodies Biobetters
    • 5.1.1.6. Anti-haemophilic Factor
    • 5.1.1.7. Others
• 5.2. Europe Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Diabetes
    • 5.2.1.2. Cancer
    • 5.2.1.3. Renal Disease
    • 5.2.1.4. Neurodegenerative Disease
    • 5.2.1.5. Genetic Disorders (Haemophilia)
    • 5.2.1.6. Others
• 5.3. Europe Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Subcutaneous
    • 5.3.1.2. Intravenous
• 5.4. Europe Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.4.1. Key Highlights
    • 5.4.1.1. Hospital Pharmacies
    • 5.4.1.2. Retail Pharmacies
    • 5.4.1.3. Online Pharmacies
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis
• 5.5. Europe Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.5.1. Key Highlights
    • 5.5.1.1. Germany Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.5.1.2. Germany Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.3. Germany Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.4. Germany Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.5. U.K. Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.5.1.6. U.K. Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.7. U.K. Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.8. U.K. Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.9. France Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.5.1.10. France Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.11. France Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.12. France Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.13. Italy Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.5.1.14. Italy Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.15. Italy Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.16. Italy Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.17. Turkey Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.5.1.18. Turkey Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.19. Turkey Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.20. Turkey Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.21. Russia Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.5.1.22. Russia Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.23. Russia Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.24. Russia Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.25. Rest of Europe Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.5.1.26. Rest of Europe Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.27. Rest of Europe Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.28. Rest of Europe Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Biobetters Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Erythropoietin Biobetters
    • 6.1.1.2. G-CSF Biobetters
    • 6.1.1.3. Interferon Biobetters
    • 6.1.1.4. Insulin Biobetters
    • 6.1.1.5. Monoclonal Antibodies Biobetters
    • 6.1.1.6. Anti-haemophilic Factor
    • 6.1.1.7. Others
• 6.2. Asia Pacific Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Diabetes
    • 6.2.1.2. Cancer
    • 6.2.1.3. Renal Disease
    • 6.2.1.4. Neurodegenerative Disease
    • 6.2.1.5. Genetic Disorders (Haemophilia)
    • 6.2.1.6. Others
• 6.3. Asia Pacific Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. Subcutaneous
    • 6.3.1.2. Intravenous
• 6.4. Asia Pacific Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.4.1. Key Highlights
    • 6.4.1.1. Hospital Pharmacies
    • 6.4.1.2. Retail Pharmacies
    • 6.4.1.3. Online Pharmacies
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis
• 6.5. Asia Pacific Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.5.1. Key Highlights
    • 6.5.1.1. China Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.5.1.2. China Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.3. China Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.4. China Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.5. Japan Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.5.1.6. Japan Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.7. Japan Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.8. Japan Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.9. South Korea Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.5.1.10. South Korea Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.11. South Korea Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.12. South Korea Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.13. India Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.5.1.14. India Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.15. India Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.16. India Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.17. Southeast Asia Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.5.1.18. Southeast Asia Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.19. Southeast Asia Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.20. Southeast Asia Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.21. Rest of Asia Pacific Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.5.1.22. Rest of Asia Pacific Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.23. Rest of Asia Pacific Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.24. Rest of Asia Pacific Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Biobetters Market Outlook, 2018 - 2031

• 7.1. Latin America Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Erythropoietin Biobetters
    • 7.1.1.2. G-CSF Biobetters
    • 7.1.1.3. Interferon Biobetters
    • 7.1.1.4. Insulin Biobetters
    • 7.1.1.5. Monoclonal Antibodies Biobetters
    • 7.1.1.6. Anti-haemophilic Factor
    • 7.1.1.7. Others
• 7.2. Latin America Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Diabetes
    • 7.2.1.2. Cancer
    • 7.2.1.3. Renal Disease
    • 7.2.1.4. Neurodegenerative Disease
    • 7.2.1.5. Genetic Disorders (Haemophilia)
    • 7.2.1.6. Others
• 7.3. Latin America Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Subcutaneous
    • 7.3.1.2. Intravenous
• 7.4. Latin America Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.4.1. Key Highlights
    • 7.4.1.1. Hospital Pharmacies
    • 7.4.1.2. Retail Pharmacies
    • 7.4.1.3. Online Pharmacies
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis
• 7.5. Latin America Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.5.1. Key Highlights
    • 7.5.1.1. Brazil Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.5.1.2. Brazil Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.5.1.3. Brazil Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.5.1.4. Brazil Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.1.5. Mexico Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.5.1.6. Mexico Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.5.1.7. Mexico Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.5.1.8. Mexico Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.1.9. Argentina Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.5.1.10. Argentina Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.5.1.11. Argentina Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.5.1.12. Argentina Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.1.13. Rest of Latin America Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.5.1.14. Rest of Latin America Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.5.1.15. Rest of Latin America Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.5.1.16. Rest of Latin America Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Biobetters Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Erythropoietin Biobetters
    • 8.1.1.2. G-CSF Biobetters
    • 8.1.1.3. Interferon Biobetters
    • 8.1.1.4. Insulin Biobetters
    • 8.1.1.5. Monoclonal Antibodies Biobetters
    • 8.1.1.6. Anti-haemophilic Factor
    • 8.1.1.7. Others
• 8.2. Middle East & Africa Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Diabetes
    • 8.2.1.2. Cancer
    • 8.2.1.3. Renal Disease
    • 8.2.1.4. Neurodegenerative Disease
    • 8.2.1.5. Genetic Disorders (Haemophilia)
    • 8.2.1.6. Others
• 8.3. Middle East & Africa Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. Subcutaneous
    • 8.3.1.2. Intravenous
• 8.4. Middle East & Africa Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.4.1. Key Highlights
    • 8.4.1.1. Hospital Pharmacies
    • 8.4.1.2. Retail Pharmacies
    • 8.4.1.3. Online Pharmacies
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis
• 8.5. Middle East & Africa Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.5.1. Key Highlights
    • 8.5.1.1. GCC Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.5.1.2. GCC Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.3. GCC Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.4. GCC Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1.5. South Africa Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.5.1.6. South Africa Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.7. South Africa Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.8. South Africa Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1.9. Egypt Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.5.1.10. Egypt Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.11. Egypt Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.12. Egypt Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1.13. Nigeria Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.5.1.14. Nigeria Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.15. Nigeria Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.16. Nigeria Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1.17. Rest of Middle East & Africa Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.5.1.18. Rest of Middle East & Africa Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.19. Rest of Middle East & Africa Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.20. Rest of Middle East & Africa Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Product vs Indication Heatmap
• 9.2. Company Market Share Analysis, 2023
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. F.Hoffmann-La Roche AG
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Product Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. Merck & Co. Inc.
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Product Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. Sanofi SA
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Product Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development
  • 9.4.4. SERVIER
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Product Portfolio
    • 9.4.4.3. Financial Overview
    • 9.4.4.4. Business Strategies and Development
  • 9.4.5. Porton Biopharma Limited
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Product Portfolio
    • 9.4.5.3. Financial Overview
    • 9.4.5.4. Business Strategies and Development
  • 9.4.6. Eli Lily and Company
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Portfolio
    • 9.4.6.3. Financial Overview
    • 9.4.6.4. Business Strategies and Development
  • 9.4.7. Novo Nordisk A/S
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Product Portfolio
    • 9.4.7.3. Financial Overview
    • 9.4.7.4. Business Strategies and Development
  • 9.4.8. Biogen Inc.
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Product Portfolio
    • 9.4.8.3. Financial Overview
    • 9.4.8.4. Business Strategies and Development
  • 9.4.9. CSL Behring GmbH
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Product Portfolio
    • 9.4.9.3. Financial Overview
    • 9.4.9.4. Business Strategies and Development
  • 9.4.10. Teva Pharmaceutical Industries Ltd.
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Product Portfolio
    • 9.4.10.3. Financial Overview
    • 9.4.10.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료